GLIMIP MF3 850SR

GLIMIP MF 3mg/850mg Sustained Release Tablet is classified as an anti-diabetic medication. It combines two active ingredients that work together to manage type 2 diabetes mellitus in adults, assisting in the regulation of blood glucose levels. To achieve optimal results, it is recommended that this medication be taken alongside food. Consistency in daily intake at the same time is important, as your healthcare provider will determine the appropriate dosage based on your individual response and blood sugar measurements. It is crucial to continue taking this medication even if you feel well or if your blood glucose is stable; discontinuing it without consulting your healthcare provider may lead to elevated blood sugar levels, which can increase the risk of serious complications such as kidney damage, vision issues, nerve problems, and limb loss. This medication should be considered part of a comprehensive diabetes management plan that includes a nutritious diet, regular physical activity, and weight management as guided by your healthcare professional. Lifestyle modifications are essential for effective diabetes control. The primary side effect associated with GLIMIP MF 3mg/850mg Tablet is hypoglycemia, or low blood sugar. It is important to recognize symptoms of low blood sugar, such as sweating, dizziness, confusion, and tremors, and to have a quick source of glucose, like sugary snacks or fruit juice, readily available. Alcohol consumption can elevate the risk of hypoglycemia and should be minimized. Other potential side effects may include alterations in taste, nausea, diarrhea, abdominal pain, headaches, and infections of the upper respiratory tract. Some patients may experience weight gain while taking this medication. It is contraindicated in individuals with type 1 diabetes, diabetic ketoacidosis, or severe renal or hepatic impairment. Inform your physician of any history of heart disease prior to use, and pregnant or nursing individuals should seek medical advice before starting treatment. Regular monitoring of blood sugar and blood tests to evaluate blood cell counts and liver function may be necessary during the therapy.